HPLC determination of plasma dimethylarginines: Method validation and preliminary clinical application

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1632-1636

  Ivanova, Mariela ^a   Artusi, Carlo ^a   Boffa, Giovanni Maria ^a   Zaninotto, Martina ^a   Plebani, Mario ^a,b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Leonardo Foundation   (Italy)

Author keywords

ADMA; Asymmetric dimethylarginine; Dimethylarginines; Endothelial dysfunction; SDMA; Symmetric dimethylarginine

Indexed keywords

6 N,N' DIMETHYLARGININE; CREATININE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FLUORESCENCE ANALYSIS; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ARGININE; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATINE; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 77956458757     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.001     Document Type: Article

References (19)

1. Cooke J.P. Asymmetric dimethylarginine: the Uber marker?. Circulation 2004, 109:1813-1818.
2. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007, 27:2037-2042.
3. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diab Care 2007, 30:1834-1839.
4. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005, 16:2456-2461.
5. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
6. Closs E.I., Basha F.Z., Habermeir A., Fostermann U. Interference of L-arginine analogue and L-arginine transport mediated by the y+carrier hCAT-2B. Nitric Oxide 1997, 1:65-73.
7. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action. Pharmacol Res 2009, 60:448-460.
8. Jessup M., Abraham W.T., Casey D.E., et al. ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
9. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diab Care 2009, 32:S62-S67.
10. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
11. de Jong S., Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 2006, 353:287-289.
12. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303:131-137.
13. Anderstam B., Katzarski K., Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997, 8:1437-1442.
14. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005, 43:1130-1138.
15. Miyazaki H., Matsuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141-1146.
16. Hov G.G., Sagen E., Bigonah A., Asberg A. Health-associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high-performance liquid chromatography. Scand J Clin Lab Invest 2007, 67:868-876.
17. Horowitz J.D., Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 851:42-50.
18. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 851:21-29.
19. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., Böger R.H. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005, 35:622-626.